Tech Company Financing Transactions
ProNAi Therapeutics Funding Round
ProNAi Therapeutics, based in Vancouver BC, scored $11.2 million in investment from Capital Midwest Fund and private investors.
Transaction Overview
Company Name
Announced On
12/31/2013
Transaction Type
Venture Equity
Amount
$11,176,453
Round
Undisclosed
Investors
Capital Midwest Fund (Lead Investor) (Alvin Vitangcol)
Proceeds Purpose
Proceeds purposes were not disclosed. Contact technology company for solicitation details, if applicable.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
885 West Georgia St. 2150
Vancouver BC, V6C 3E8
Canada
Vancouver BC, V6C 3E8
Canada
Phone
Website
Email Address
Overview
ProNAi Therapeutics, Inc. (NASDAQ: DNAI) is a biopharmaceutical company that is leveraging its novel and proprietary nucleic acid-based interfering technology, DNAi, to advance a next generation of therapies for patients with cancer and other complex genetic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Nick Glover
Chief Financial Officer
Sukhi Jagpal
VP - Human Resources
Diane Gardiner
VP - Manufacturing
Simon Eastman
VP - Operations
Wendy Chapman
VP - R & D
Emma McCann
VP - Regulatory Affairs
Chandra Lovejoy
Browse more venture capital transactions:
Prev: 12/31/2013: Axenic Dental venture capital transaction
Next: 12/31/2013: Techneed venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. All VC database entries on this site are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs